Ng George K

CEO George K Ng bought 2,034 shares at $2.69 on 2026-04-30; 51.1% increase in holdings amid cluster buy pattern and extreme valuation pressures ($7.0M market cap, -78.7% from 52-week high).

CEO George K Ng purchased 2,034 shares of PCSA at $2.69, increasing his holdings by 51.1% from 3,979 to 6,013 shares. This follows a cluster buy pattern: 5 other insiders also bought within the past 14 days, suggesting coordinated board or management-level confidence signals. His same-ticker trade history at PCSA shows strong execution: his prior buy on 2025-01-27 returned +643.6% over 90 days, and his 2024-01-30 buy returned +1844.4% over 90 days—a 2 of 2 well-timed rate at the 90-day mark. However, the current fundamentals are severe: the company reported $0.00 revenue in the latest quarter, negative net income of $-3,436,573.00, and a $7.0M market cap. The stock trades -78.7% from its 52-week high of $11.97 and has declined -15.0% over the past 90 days. The cluster buy during an extreme valuation trough combined with CEO scale-up (51.1% portfolio expansion) and his demonstrated ability to identify turning points at this ticker warrants close monitoring, though the company's lack of revenue and persistent unprofitability pose material execution risk.

CEO George K Ng bought 1,843 shares of PCSA at $2.97 on 2026-04-15; stock -74.1% from 52-week high, cluster buy by 5 other insiders within 14 days.

CEO Ng purchased 1,843 shares at $2.97, increasing his holdings by 50.5% to 5,492 shares. The purchase occurs at a steep discount to the 52-week high of $11.97, with the stock currently trading at $3.10, down 12.4% over 90 days. His prior two purchases at PCSA (2025-01-27 and 2024-01-30) both delivered strong 90-day returns of +643.6% and +1844.4% respectively, establishing a 2-for-2 well-timed buying pattern at this ticker. Critically, this purchase is part of a broader insider cluster: 5 other insiders bought within the past 14 days. However, this must be contextualized against fundamentals—the company generated $0.00 in revenue during the latest quarter with a net loss of $-3,436,573.00 and a market cap of only $8,246,120.90. The coordinated buying activity by multiple insiders during a severe drawdown warrants scrutiny, but the company's zero revenue and significant unprofitability constrain the predictive power of insider transactions alone.

CEO George K Ng bought 2,136 shares of PCSA at $2.54; 2 of 2 prior PCSA buys returned +643.6% and +1844.4% over 90 days; 8 other insiders bought within 14 days.

George K Ng, CEO of Processa Pharmaceuticals, purchased 2,136 shares at $2.54, increasing his position by 141.2% to 3,649 shares post-transaction. This buy occurs in a cluster pattern, with 8 other insiders purchasing within the past 14 days. His prior trades at PCSA show a striking pattern: a buy on 2025-01-27 returned +1614.7% over 30 days and +643.6% over 90 days, and a buy on 2024-01-30 returned +2177.8% over 30 days and +1844.4% over 90 days, with both achieving positive 90-day returns. The company is unprofitable with revenue of $0.00 in the latest quarter and a net loss of $-3,436,573.00, though the stock is currently trading 78.3% below its 52-week high of $11.97. The convergence of a cluster buy, prior successful timing at this ticker, and the company's extreme financial stress creates a high-stakes signal that warrants examination of whether a pending catalyst or restructuring is imminent.

CEO George K Ng buys 87.2K shares at $0.80; stock down 88.4% from 52-week high; cluster buy pattern with 3 other insiders in 14 days

CEO George K Ng purchased 87,200 shares at $0.80 on 2025-01-27, establishing an initial position in PCSA. The timing follows a sharp decline—the stock is down -88.4% from its 52-week high of $127.50 and has fallen -35.6% over 30 days and -48.7% over 90 days—suggesting the purchase occurred after material price deterioration. Notably, 3 other insiders also bought within the past 14 days, forming a cluster buy pattern that indicates alignment among multiple executives. The company faces significant headwinds: it reported $0.00 revenue in the latest quarter, a net loss of $-3,384,703.00, and remains unprofitable on a full-year basis, with a market cap of $48,383,440.64. The CEO's purchase represents his first equity stake, warranting investor scrutiny into whether this reflects conviction about recovery potential or signals being made in response to operational stress.